Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Propranolol→

Propranolol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
525-66-6
Molecular formula
C16H21NO2
Molecular weight
259.34 g/mol
Drug class
Nonselective beta-adrenergic receptor antagonistBeta-adrenergic blocking agent
Mechanism of action
Competitively blocks beta-adrenergic receptors, reducing chronotropic, inotropic and other responses to beta-adrenergic stimulation. The precise mechanism of its antihypertensive effect has not been established.
Indications / reported uses
  • Hypertension
  • Angina pectoris due to coronary atherosclerosis
  • Control of ventricular rate in atrial fibrillation
  • Reduction of cardiovascular mortality after acute myocardial infarction in clinically stable patients
  • Prevention of common migraine
  • Essential tremor

Sources: DailyMed — Propranolol hydrochloride prescribing information (indications) · DailyMed — Propranolol hydrochloride prescribing information (clinical pharmacology)

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Propranolol Environmental Risk Assessment (ERA) (the Propranolol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.